On March 19, 2026 Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, reported that the China National Intellectual Property Administration (CNIPA) has granted a new patent for Radspherin, the Company’s lead product candidate, marking the first approval worldwide within this patent family.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The newly granted patent covers a key technical development to optimize Radspherin’s performance, specifically the size-controlled calcium carbonate microparticle technology. With this grant, patent protection for Radspherin in China is expanded in scope and duration, with a term extending to 2041. This complements the existing composition‑of‑matter patent, which is valid until 2035 (2036 in some jurisdictions). Corresponding patent applications from the same patent family remain under review in several major jurisdictions worldwide.

"We are very pleased to obtain this additional patent in China for Radspherin," said Oystein Soug, Chief Executive Officer at Oncoinvent. "As we continue to advance clinical development, it is essential that our innovation is backed by a strong and durable global intellectual property position."

(Press release, Oncoinvent, MAR 19, 2026, https://www.oncoinvent.com/press-release/oncoinvent-secures-new-patent-expanding-protection-for-radspherin/ [SID1234663708])

On March 19, 2026 Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), reported it will hold an oral presentation outlining new preclinical data on Radio-DARPins at the 3rd Global Radiopharmaceuticals Development Summit, taking place in Shanghai, China on March 19–20, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will outline the Radio-DARPins’ suitability to different isotopes with data on two Radio-DARPin candidates, each specific for a different tumor target. The results of studies in tumor-bearing mice show highly comparable biodistribution profiles for both Radio-DARPin candidates labeled with Lutetium-177 (177Lu) or with Lead-203 (203Pb), with similar uptake and washout rates. Imaging with 177Lu can be indicative of behavior with the therapeutic isotope Actinium-225 (225Ac), and similarly with 203Pb for 212Pb.

"Our recent data confirms that our Radio-DARPin-vector design allows interchangeability of alpha-isotopes, including 212Pb and 225Ac," said Patrick Amstutz, Ph.D., CEO of Molecular Partners. "This feature offers us the opportunity and flexibility to evaluate Radio-DARPin candidates in an isotope-agnostic manner and to choose the most suitable therapeutic isotope, as late as with initial clinical data, without having to restart the entire drug discovery and development process – a significant advantage to tailor our candidates to patient needs."

Details of the presentation

DARPins for targeted alpha therapy: from promising MP0712 first in-human data to opportunities for next Radio-DARPin candidates
Presenter: Daniel Steiner, Ph.D., SVP of Technology and Research
Time: 9:25 am CST, Friday, March 20
Location: Meeting Room B – IND Filing and Clinical Development Progress

The full presentation can be found here.

MP0712, Molecular Partners’ DLL3-targeted 212Pb-based Radio-DARPin candidate co-developed with strategic partner Orano Med, is in an ongoing Phase 1/2a trial in the US (NCT07278479). Imaging data of MP0712 carrying the diagnostic isotope 203Pb under compassionate care are supportive of clinical development plans of MP0712 carrying the therapeutic isotope 212Pb for patients with small cell lung cancer (SCLC) and other DLL3-expressing neuroendocrine cancers.

In February 2026, Molecular Partners entered into an agreement with Eckert & Ziegler, leading specialist in isotope-related components for nuclear medicine and radiation therapy, to enable the development and manufacturing of Radio-DARPin therapeutics. Eckert & Ziegler will support Molecular Partners with a comprehensive range of services covering development activities for Radio-DARPins with 225Ac as therapeutic payload and 177Lu as imaging payload.

About Radio-DARPins
Molecular Partners’ Radio-DARPins are designed as ideal vectors for precise delivery of potent alpha-emitting isotopes to tumor lesions and have the potential to unlock a broad range of tumor targets for targeted radiopharmaceuticals. Building on the DARPins’ unique properties, Molecular Partners has developed a proprietary Radio-DARPin platform to address historic limitations of radioligand therapy, such as kidney accumulation and toxicity, and suboptimal tumor uptake. Molecular Partners’ Radio-DARPins addresses these limitations through half-life extension technologies and surface engineering approaches, while preserving the advantages of the small protein format.

(Press release, Molecular Partners, MAR 19, 2026, View Source [SID1234663707])

On March 28, 2026 XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its 2025 fourth quarter and full year financial results and highlighted recent actions that have the potential to deliver additional shareholder value.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We continue to search for innovative ways to drive enhanced optionality in the XOMA portfolio, with the addition of 22 assets and two platform technologies over the past year," stated Owen Hughes, Chief Executive Officer of XOMA Royalty. "With multiple commercial assets delivering growing royalty receipts, we achieved positive cash flow from operations and were able to return $16 million of capital through a share buyback in 2025. Looking ahead, with 14 programs in registrational studies, we anticipate a number of catalysts over the ensuing years, including several regulatory updates and late-stage clinical readouts in 2026, which, if positive, will further diversify our commercial royalty streams and drive growing free cash flow in 2027 and beyond."

Portfolio Updates

Day One
•

OJEMDA New Drug Application filing in Japan triggered $2 million milestone in 4Q25

•

OJEMDA FY 2026 revenue guidance of $225 – $250 million2

•

In February 2026, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the conditional marketing authorization of OJEMDA3

•

In March 2026, Day One and Servier announced that they have entered into a definitive agreement for Servier to acquire Day One for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion4

Zevra Therapeutics
•

A Marketing Authorization Application for the evaluation of arimoclomol (MIPLYFFA) for the treatment of NPC is under review by the EMA5

Rezolute
•

In December 2025, Rezolute announced that the Phase 3 clinical study of ersodetug for the treatment of congenital hyperinsulinism ("HI") demonstrated reductions from baseline in hypoglycemia events by self-monitored blood glucose at both ersodetug dose levels, but the reductions were not statistically significant compared to placebo, due to a pronounced study effect6

•

Rezolute will meet with FDA under its Breakthrough Therapy Designation in the first quarter of 2026 to determine next steps for the program6

•

Rezolute anticipates topline results of upLIFT, a Phase 3, single-arm, open-label study in participants with tumor HI, in the second half of 20266

Gossamer Bio & Chiesi
•

In February 2026, Gossamer Bio announced topline results from the Phase 3 PROSERA clinical trial evaluating seralutinib for the treatment of PAH7

•

Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.0257

•

Gossamer plans to meet with the U.S. FDA to discuss the path forward7

2
View Source

3
View Source
children-with-relapsed-or-refractory-braf-altered-pediatric-low-grade-glioma-3246394/

4
View Source

5
View Source

6
View Source

7
View Source

Volixibat
•

Volixibat VISTAS study in primary sclerosing cholangitis (PSC) topline data expected in Q2 20268

•

Volixibat VANTAGE study in primary biliary cholangitis (PBC) expected to complete enrollment in H2 20268

Business Development Activity

Takeda Strategic Royalty Share Transaction
•

In December 2025, XOMA amended its collaboration with Takeda

•

XOMA will receive low to mid-single-digit royalties and up to $852.6 million in potential milestones across nine development-stage assets, including osavampator, which is being evaluated in Phase 3 studies for major depressive disorder; volixibat, which is being evaluated in PSC and PBC; OHB-607, which Oak Hill Bio Ltd and its partner are developing for the prevention of bronchopulmonary dysplasia in extremely premature infants; REC-4881, which is in Phase 2 development for familial adenomatous polyposis; and five early-stage Oak Hill Bio assets

•

Prior to amending the collaboration, XOMA held a mid-single digit royalty and $16.25 million in potential milestones associated with mezagitamab

•

Following the transaction, XOMA will retain a low single-digit royalty entitlement on mezagitamab and up to $13.0 million in milestones

Company Acquisitions
•

Completed or served as the structuring agent in the acquisition of seven companies since the beginning of 2025

•

Accumulated non-dilutive capital of $11.7 million, net of transaction expenses

•

Obtained economic interests of approximately 25% in up to $1.1 billion of potential milestone payments and low to mid-single-digit royalties from eight partnered assets

•

Eligible for 25-70% of proceeds related to any future out license or sale of legacy assets or platform technology from these companies, including the ctLNP delivery platform from Generation Bio

Fourth Quarter and Full-Year 2025 Financial Results

In the fourth quarter of 2025, XOMA Royalty received $3.2 million in cash receipts from royalties and commercial payments and $3.3 million in milestone payments and paid $1.4 million in dividends on the XOMA Royalty Perpetual Preferred stocks. For the full year of 2025, XOMA Royalty received $50.5 million in cash receipts, including $33.6 million in royalties and commercial payments and $16.9 million in milestone payments and fees. During 2025, XOMA Royalty deployed $25.0 million to acquire additional assets for its royalty and milestone portfolio, repurchased 648,048 shares of its common stock for a cost of $16.0 million, and paid $5.5 million in dividends on the XOMA Royalty Perpetual Preferred stocks.

Income and Revenue: Income and revenues for the three months ended December 31, 2025 and 2024, were $13.8 million and $8.7 million, respectively. Income and revenues for the years ended December 31, 2025 and 2024, were $52.1 million and $28.5 million, respectively. The increase in both periods was primarily driven by increased income related to VABYSMO (faricimab-svoa) and OJEMDA (tovorafenib) and milestone payments received from Rezolute and Takeda.

(Press release, Xoma, MAR 18, 2026, View Source [SID1234663757])

On March 18, 2026 Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, reported the publication of foundational research in Nature describing in vivo site-specific genomic integration to reprogram T cells. The research originated as an academic collaboration between the Eyquem laboratory at the University of California, San Francisco and the Doudna laboratory at the University of California, Berkeley. Three of the study’s authors – Justin Eyquem, Ph.D., Jenny Hamilton, Ph.D. and Jennifer Doudna, Ph.D. – subsequently co-founded Azalea Therapeutics to advance precise, programmable in vivo cell engineering toward the development of next-generation in vivo CAR T and other cell-based therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The publication, titled "In vivo site-specific engineering to reprogram T cells," demonstrates that stable and cell-specific transgene expression can be achieved through in vivo integration of large DNA payloads using a two-vector system consisting of enveloped delivery vehicles (EDVs) and adeno-associated viruses (AAVs). In preclinical models, the approach enabled targeted integration of a promoterless chimeric antigen receptor (CAR) transgene at the TRAC locus, resulting in physiologic CAR expression, robust T cell expansion and durable anti-tumor activity.

The research shows that placing CAR expression under control of the endogenous T cell receptor alpha (TRAC) promoter produces regulated CAR expression compared to conventional approaches relying on random integration or constitutive exogenous promoters. In humanized mouse models of B cell aplasia and hematologic malignancies, in vivo-generated TRAC-CAR T cells achieved therapeutic levels of CAR-positive T cells and sustained tumor control.

"This work demonstrates that stable, cell-specific transgene expression can be achieved through in vivo site-specific integration," said Justin Eyquem, Ph.D., co-founder of Azalea Therapeutics and associate professor of medicine at UCSF. "By integrating a promoterless CAR into the TRAC locus, we place expression under control of the endogenous T cell promoter, resulting in physiologic regulation and durable functional activity in preclinical models. These findings establish a foundation for precise in vivo T cell engineering without ex vivo manufacturing."

The research further describes optimization of both delivery components, including evolution of an AAV variant for improved T cell targeting and incorporation of an anti-CD3-targeted EDV to enhance specificity and activation. In humanized mouse models, the optimized system enabled generation of TRAC-CAR T cells representing up to ~20% of splenic T cells following a single administration, accompanied by complete B cell aplasia and tumor clearance.

"The research described in this publication establishes the scientific foundation for precise, programmable CAR insertion directly inside the body," said Jenny Hamilton, Ph.D., co-founder, president and chief executive officer of Azalea Therapeutics. "At Azalea, we are building on these findings with our proprietary EDV-based platform to advance in vivo CAR T programs toward clinical development. Our goal is to generate physiologically regulated, durable CAR T cells in patients through targeted genomic integration, while avoiding the complexity of ex vivo cell manufacturing."

Azalea is advancing TRAC-targeted in vivo CAR T programs toward IND-enabling studies, building on the foundational work described in this publication, which is available online in Nature.

(Press release, Azalea Therapeutics, MAR 18, 2026, View Source [SID1234663733])

On March 18, 2026 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, reported that it will present four posters at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 17–22 at the San Diego Convention Center in San Diego, California. The presentations will include one poster featuring data from BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor (ClinicalTrials.gov identifier: NCT06072612), two posters highlighting further analyses of Phase 2 data, and one poster presenting preclinical data related to Bria-OTS+, BriaCell’s next-generation personalized off-the-shelf immunotherapy for cancer. Abstracts will be published in the online Proceedings of the AACR (Free AACR Whitepaper).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"With four posters presenting positive clinical and preclinical data, we are expanding the body of evidence supporting the efficacy and favorable safety profile of our novel immunotherapy, with the goal of improving care for patients with cancer who remain in urgent need of new treatment options," stated William V. Williams, MD, BriaCell’s President & CEO.

Session Title: Phase II and Phase III Clinical Trials
Session: 4/20/2026 2:00-5:00 PM
Location: Poster Section 52
Poster Board Number: 1
Poster Number: CT137
Title: QOL Outcomes in Bria-ABC Late-Stage Metastatic Phase 3 Trial
Summary: Heavily pretreated metastatic breast cancer patients in the pivotal Phase 3 study of Bria-IMT plus an immune check point inhibitor maintained overall health status and key functional measures with a favorable safety profile. These findings are encouraging because they suggest meaningful preservation of quality of life for late-stage metastatic breast cancer patients with limited treatment options.

Session Category: Clinical Research
Session Title: Vaccines and Other Immunomodulatory Agents
Session: 4/21/2026 2:00-5:00 PM
Location: Poster Section 49
Poster Board Number: 12
Poster Number: 6701
Title: Re-Engineering Cancer Vaccines: Bria-OTS+ Integrates Innate and Adaptive Immunity for Broad and Persistent Anti-Tumor Responses
Summary: Bria-OTS+ is a personalized off-the-shelf next-generation, genetically engineered whole-cell cancer immunotherapy platform designed for better efficacy and safety. Our findings indicated that Bria-OTS+ immunotherapy targeting breast, prostate, lung and melanoma activated key components of both the innate and adaptive immune system to broadly attack and destroy cancer cells. These include coordinated activation of CD4⁺/CD8⁺ T, NK, NKT and B cells, increased cytokine release and persistent immune competence without exhaustion – combating a known cause of cancer progression.

Session Category: Clinical Research
Session: 4/19/2026 2:00-5:00 PM
Location: Poster Section 42
Poster Board Number: 5
Poster Number: 1065
Title: Mitosis in Circulating Tumor Cells Correlates with Highly Aggressive Disease in Metastatic Breast Cancer

Session Category: Clinical Research
Session Title: Biomarkers Predictive of Therapeutic Benefit 1
Session: 4/19/2026 2:00-5:00 PM
Location: Poster Section 40
Poster Board Number: 19
Poster Number: 1025
Title: Monitoring PD-L1 in tumor macrophage fusion cells in blood identifies high PD-L1 checkpoint inhibitor responses in metastatic breast cancer

Following the presentation, copies of the posters will be made available at View Source

(Press release, BriaCell Therapeutics, MAR 18, 2026, View Source [SID1234663732])